Abstract: New compounds of formula: ##STR1## wherein: A represents alkyl, alkenyl, alkynyl, cycloalkylalkyl or aralkyl, andE represents: ##STR2## in racemic form or in the form of optical isomers, and the addition salts thereof with pharmaceutically acceptable acids.Those compounds may be used as medicaments.

Abstract: Compounds of formula (I): in which:R.sub.a and R.sub.b, identical or different, represent hydrogen or alkyl or together form a bond,R.sub.C represents hydroxyl optionally substituted alkoxy, or optionally substituted amino,R.sub.1 represents hydrogen or --O--NO.sub.2, --O--NO, or --S--NO,R.sub.2 and R.sub.3, identical or different, represent hydrogen, alkyl, or optionally substituted phenyl,X represents oxygen or --NH--CO--,m represents 0 or 1,n represents an integer such that 0.ltoreq.n.ltoreq.6,p represents 0 or 1,R.sub.4 represents hydrogen, optionally substituted alkyl, optionally substituted phenyl, or a group as defined in the description,R.sub.5 represents hydrogen or alkyl,R.sub.6 represents hydrogen or alkyl,or R.sub.5 and R.sub.6 together form a chain --(CH.sub.2).sub.t -- in which t represents 1 or 2,q represents 0, 1, or 2,r represents an integer such that 0.ltoreq.r.ltoreq.6,R.sub.d and R.sub.

Abstract: This invention relates to benzofuran/pyran derivatives of a new tricyclic amide compound, their composition and method of use for treating disorders of the melatoninergic system.

Abstract: A novel pharmaceutical composition allowing the programmed release of dexfenfluramine containing a water-soluble acid addition salt of dexfenfluramine on a mixture of minigranules, both rapid release and slow release minigranules, permits the attainment of two concentration peaks in the plasma of patients treated therewith.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents halogen or hydroxyl, alkoxy, trihalomethyl, amino, mercapto, alkylthio, trialkylammonium, aryloxy, arylthio, arylsulfonyl, arylsulfonyloxy, cycloalkyloxy, cycloalkylthio, bicycloalkyloxy or bicycloalkylthio,R.sub.a and R.sub.b, which may be identical or different, represent hydrogen or alkyl,X represents oxygen or sulfur or NR,Y represents the group as defined in the description,R.sub.2 represents an optionallly substituted aryl,its optical isomers as well as its addition salts with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as interleukin-1.beta. inhibitor.

Abstract: New 2-aminoindan compounds of formula: ##STR1## wherein: n, Ar, R, E, X.sub.1, X.sub.2, X.sub.3, and X.sub.4 are as defined in the description, in the form of a racemic mixture and in the form of optical isomers, and physiologically-tolerable acid addition salts thereof. The products of the invention are useful as medicaments and exhibit selective binding affinity for the 5HT.sub.1B receptors.

Abstract: New N-arylpiperidine compounds of formula: ##STR1## wherein: A, m, R, E, n and Ar are as defined in the description, the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful in the treatment of disorders involving the serotininergic system.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1, R.sub.2, A and B are as defined in the description, their optical isomers, N-oxides and addition salts with a phar-maceutically acceptable acid, and their use as anti-tumor agents.

Abstract: A compound of formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, X-Y, A, Z and Z' are as defined in the description, in the form of the cis or trans isomers each in racemic or optically active form, and acid addition salts thereof, and medicinal products containing the same are useful in the treatment of diseases of the central nervous system or of manifestations of pain.

Abstract: The invention relates to a nasal pharmaceutical preparation suitable for nasal administration containing a progestogen and a methylated .beta.-cyclodextrin having a degree of substitution of between 0.5 and 3.0 and hard gelatin capsules containing the same.

Abstract: New amino compounds of formula: ##STR1## wherein n and Y are as defined in the description, in racemic form or in the form of optical isomers.and addition salts thereof with pharmaceutically acceptable acids.Those compounds may be used as medicaments.

Abstract: Compound of formula (I): in which R is as defined in the description, as well as their isomers and their pharmaceutically acceptable acid additions salts. Medicinal products containing the same are useful as Imidazoline receptors ligand.

Abstract: The invention relates to compound of general formula (I): ##STR1## wherein: Z represents O or CH.sub.2n is from 0 to 4R, X and Y are as defined in the description, andA represents ##STR2## wherein R.sup.1, R.sup.2, R.sup.6, R.sup.7 and T' are as defined in the description,and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.

Abstract: A compound of general formula (I): ##STR1## where A, X, R.sub.1, Y, n and Ar are defined in the description. Medicinal products containing the same are useful as D.sub.4 receptor Ligands.

Abstract: New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.

Abstract: The compounds of formula: ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and A are as defined in the description, their optical isomers and N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as anti-tumour agents.

Abstract: The present invention relates to a new mucoadhesive pharmaceutical composition which makes possible the prolonged release of active pharmaceutical principles in the buccal cavity or via the transmucosal route.

Abstract: Articles which it is intended to sterilize are placed into a confined volume and are subjected to neutral species of an electrical discharge while maintaining the volume glowless and substantially field free by interposing a barrier between the articles and the discharge, the barrier being transparent to neutral species and opaque to charged species emanating from the discharge.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents alkyl,R.sub.2, R.sub.4 and R.sub.5, which may be identical or different, represent hydrogen or alkyl,R.sub.3 represents any one of the groups as defined in the description,X represents carbonyl or methylene,Y represents hydrogen or alkyl or aryl,A represents single bond or alkylphenyl,R.sub.6 represents any one of the groups as defined in the description, its isomers as well as its addition salts with a pharmaceutically acceptable acid or base,and medicinal productes containing the same are useful in the treatment of diabetes and complications of diabetic disease.

Abstract: The invention relates to a matrix tablet for the prolonged release of the sodium salt of tianeptine which ensures a continuous and uniform release of the active ingredient after administration by the oral route.